HRP20200897T1 - Parenteralna formulacija esmolola - Google Patents

Parenteralna formulacija esmolola Download PDF

Info

Publication number
HRP20200897T1
HRP20200897T1 HRP20200897TT HRP20200897T HRP20200897T1 HR P20200897 T1 HRP20200897 T1 HR P20200897T1 HR P20200897T T HRP20200897T T HR P20200897TT HR P20200897 T HRP20200897 T HR P20200897T HR P20200897 T1 HRP20200897 T1 HR P20200897T1
Authority
HR
Croatia
Prior art keywords
solution
formulation
esmolol hydrochloride
use according
ready
Prior art date
Application number
HRP20200897TT
Other languages
English (en)
Croatian (hr)
Inventor
Rudolf Widmann
Original Assignee
Aop Orphan Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48407551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20200897(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aop Orphan Pharmaceuticals Ag filed Critical Aop Orphan Pharmaceuticals Ag
Publication of HRP20200897T1 publication Critical patent/HRP20200897T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20200897TT 2012-05-10 2013-05-08 Parenteralna formulacija esmolola HRP20200897T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12167443 2012-05-10
EP13721740.2A EP2846776B1 (en) 2012-05-10 2013-05-08 Parenteral esmolol formulation
PCT/EP2013/059594 WO2013167657A1 (en) 2012-05-10 2013-05-08 Parenteral esmolol formulation

Publications (1)

Publication Number Publication Date
HRP20200897T1 true HRP20200897T1 (hr) 2020-11-27

Family

ID=48407551

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200897TT HRP20200897T1 (hr) 2012-05-10 2013-05-08 Parenteralna formulacija esmolola

Country Status (27)

Country Link
US (3) US20150087704A1 (enExample)
EP (1) EP2846776B1 (enExample)
JP (1) JP6220383B2 (enExample)
CN (1) CN104379134A (enExample)
AU (1) AU2013258031B2 (enExample)
BR (1) BR112014027870B1 (enExample)
CA (1) CA2872953C (enExample)
CL (1) CL2014003028A1 (enExample)
DK (1) DK2846776T3 (enExample)
EA (1) EA032344B1 (enExample)
ES (1) ES2794093T3 (enExample)
HR (1) HRP20200897T1 (enExample)
HU (1) HUE049314T2 (enExample)
IL (1) IL235497A0 (enExample)
LT (1) LT2846776T (enExample)
MA (1) MA37500B1 (enExample)
MX (1) MX374771B (enExample)
MY (1) MY173900A (enExample)
NZ (1) NZ701429A (enExample)
PH (1) PH12014502494B1 (enExample)
PL (1) PL2846776T3 (enExample)
PT (1) PT2846776T (enExample)
SI (1) SI2846776T1 (enExample)
TN (1) TN2014000464A1 (enExample)
UA (1) UA115333C2 (enExample)
WO (1) WO2013167657A1 (enExample)
ZA (1) ZA201408149B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019122157A1 (en) * 2017-12-21 2019-06-27 Ipsol Ag A lyophilisate comprising esmolol and adenosine for use in cardioplegia
CN111848420A (zh) * 2020-07-22 2020-10-30 杭州煌森生物科技有限公司 一种盐酸艾司洛尔的新晶型及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310094B1 (en) * 2001-01-12 2001-10-30 Baxter International Inc. Ready-to-use esmolol solution
TWI277414B (en) 2001-01-12 2007-04-01 Baxter Int Esmolol formulation
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
KR20080039954A (ko) * 2005-08-31 2008-05-07 오노 야꾸힝 고교 가부시키가이샤 점적용 주사제
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
ES2397126T3 (es) 2007-12-21 2013-03-04 Aop Orphan Pharmaceuticals Ag Composición farmacéutica para la administración parenteral de un antagonista del receptor beta-adrenérgico de acción ultrarrápida
CN102106846A (zh) * 2009-12-23 2011-06-29 南京海辰药业有限公司 左旋盐酸艾司洛尔药物组合物及其制备方法

Also Published As

Publication number Publication date
CA2872953A1 (en) 2013-11-14
EA032344B1 (ru) 2019-05-31
EP2846776A1 (en) 2015-03-18
US20220249424A1 (en) 2022-08-11
EP2846776B1 (en) 2020-04-15
ES2794093T3 (es) 2020-11-17
TN2014000464A1 (en) 2016-03-30
BR112014027870A2 (pt) 2017-06-27
PH12014502494A1 (en) 2015-01-12
JP2015520142A (ja) 2015-07-16
MA37500B1 (fr) 2016-12-30
HUE049314T2 (hu) 2020-09-28
NZ701429A (en) 2016-04-29
BR112014027870B1 (pt) 2023-04-25
US20150087704A1 (en) 2015-03-26
PL2846776T3 (pl) 2020-09-21
US11963940B2 (en) 2024-04-23
SI2846776T1 (sl) 2020-08-31
HK1204265A1 (en) 2015-11-13
ZA201408149B (en) 2016-08-31
MX2014013556A (es) 2015-01-16
AU2013258031A1 (en) 2014-11-20
CA2872953C (en) 2020-04-07
DK2846776T3 (da) 2020-06-15
PT2846776T (pt) 2020-05-28
EA201491841A1 (ru) 2015-02-27
WO2013167657A1 (en) 2013-11-14
CN104379134A (zh) 2015-02-25
LT2846776T (lt) 2020-06-25
BR112014027870A8 (pt) 2023-01-17
US20170326095A1 (en) 2017-11-16
AU2013258031B2 (en) 2017-08-03
MY173900A (en) 2020-02-26
UA115333C2 (uk) 2017-10-25
CL2014003028A1 (es) 2015-06-19
JP6220383B2 (ja) 2017-10-25
PH12014502494B1 (en) 2019-11-13
IL235497A0 (en) 2014-12-31
MA37500A1 (fr) 2016-03-31
MX374771B (es) 2025-03-06

Similar Documents

Publication Publication Date Title
Ma et al. Combining ECMO with IABP for the treatment of critically Ill adult heart failure patients
CA2703234C (en) An inhalable dry powder formulation comprising glp-1 for use by pulmonary inhalation
HRP20220470T1 (hr) Uporaba landiolol hidroklorida u dugotrajnom liječenju tahiaritmija
RU2367477C1 (ru) Способ лечения хронической ишемии нижних конечностей
Petrov An electrocardiographic sine wave in hyperkalemia
CN103393715B (zh) 钠钾镁钙葡萄糖注射液及其制备方法
CN115919824B (zh) Am404在制备防治心肌缺血再灌注损伤药物中的应用
JP6629850B2 (ja) 汎用心停止液（変種）
JP2015520142A5 (enExample)
JP2016510040A5 (enExample)
CN117257803B (zh) 鲁拉西酮在制备治疗或预防缺血/再灌注损伤的药物和细胞保护药物中的应用
CN108815171A (zh) 25-羟基胆固醇在制备治疗或预防心肌梗死的药物中的应用
CN116785435B (zh) Ep3受体拮抗剂l-798106在制备预防心肌缺血再灌注损伤药物中的应用
JP6153838B2 (ja) 血管透過性抑制剤
CN105311040A (zh) 一种含有果糖二磷酸钠的用于治疗循环系统疾病的新药物组合物针剂
Richetta et al. Efficacy of electrochemotherapy in ulcerated basal cell carcinoma
CN112209834A (zh) 一种有机亚硝酸根供体及其制备方法与医药用途
Han et al. Valve replacement for valvular heart disease with giant left ventricle
CN102028939B (zh) 一种有效成分含有水蛭素的药物
CN102028938B (zh) 一种具有活血化瘀作用的药物
MX2014013556A (es) Formulacion parenteral de esmolol.
RU2568911C1 (ru) Средство для кардиоплегии (варианты)
CN107375310A (zh) 延龄草苷在制备治疗心力衰竭药物中的用途
RU2006142622A (ru) Способ лечения острого инфаркта миокарда
HK40087636A (en) Universal cardioplegic solution (variants)